암 지지요법제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Supportive Care Drugs Market size is expected to reach USD 31.90 Billion in 2034 from USD 25.79 Billion (2025) growing at a CAGR of 2.39% during 2026-2034.

The global cancer supportive care drugs market has grown as healthcare providers focus on improving the quality of life for patients undergoing cancer treatment. These drugs are designed to manage the side effects of therapies such as chemotherapy, radiation, and immunotherapy. They help alleviate symptoms such as pain, nausea, infections, and fatigue, enabling patients to better tolerate intensive cancer treatments.

Several factors are driving the expansion of the cancer supportive care drugs market. Increasing global cancer incidence and the growing use of advanced treatment methods have created greater demand for supportive medications. Healthcare systems are placing greater emphasis on comprehensive patient care that addresses both disease management and treatment-related side effects.

Looking forward, the market is expected to grow as oncology research continues to develop new treatment options. Pharmaceutical companies are investing in innovative supportive care drugs that enhance patient comfort and treatment outcomes. Expanding access to cancer care and improved healthcare infrastructure may also contribute to the long-term growth of this market.

MARKET SEGMENTATION

By Type

• Erythropoiesis Stimulating Agents
• Granulocyte Colony Stimulating Factors
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti Inflammatory Drugs
• Others

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

COMPANIES PROFILED

• Baxter International Inc, Helsinn Healthcare SA, F HoffmannLa Roche AG, Pfizer Inc, Amgen Inc, Johnson Johnson, Heron Therapeutics Inc, Merck Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Erythropoiesis Stimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Granulocyte Colony Stimulating Factors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antiemetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bisphosphonates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Opioids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Nonsteroidal Anti Inflammatory Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER SUPPORTIVE CARE DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Baxter International Inc
  • 9.2.2 Helsinn Healthcare SA
  • 9.2.3 F. Hoffmann-La Roche AG
  • 9.2.4 Pfizer Inc
  • 9.2.5 Amgen Inc
  • 9.2.6 Johnson & Johnson
  • 9.2.7 Heron Therapeutics Inc
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 Teva Pharmaceutical Industries Ltd
  • 9.2.10 Novartis AG